Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 8/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1330301 | 0.91 | AXL (0.60) | AXLMAPK1AURKBKDRFGFR1 | |
| SCHEMBL1330480 | 0.89 | AXL (0.61) | AXLMAPK1AURKBKDRFGFR1 | |
| SCHEMBL1331395 | 0.87 | AXL (0.59) | AXLAURKBKDRFGFR1DDR2 | |
| SCHEMBL1332041 | 0.86 | KDR (0.69) | AXLAURKBKDRFGFR1DDR2 | |
| SCHEMBL1331695 | 0.85 | AURKB (0.61) | AXLMAPK1AURKBKDRFGFR1 | |
| SCHEMBL1331066 | 0.85 | AXL (0.56) | AXLAURKBKDRFGFR1DDR2 | |
| SCHEMBL1331376 | 0.85 | AXL (0.56) | AXLMAPK1KDRFGFR1DDR2 | |
| SCHEMBL1330237 | 0.83 | FGFR1 (0.70) | AXLAURKBKDRFGFR1DDR2 | |
| SCHEMBL1331973 | 0.82 | AXL (0.58) | AXLMAPK1AURKBKDRFGFR1 | |
| SCHEMBL1330486 | 0.81 | KDR (0.62) | AXLMAPK1AURKBKDRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293738-B2 | Indazole inhibitors of kinase | ABBOTT LABORATORIES (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110281868-A1 | INDAZOLE INHIBITORS OF KINASE | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281868-A1 | INDAZOLE INHIBITORS OF KINASE | AURKA, AURKC, AURKB | AXL 399/4885MAPK1 302/4885AURKB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.